“We wanted to understand the reasons why people are using cannabis medically, and whether those reasons for use are evidence-based,” said lead author Kevin Boehnke. He’s an investigator at University of Michigan’s Chronic Pain and Fatigue Research Center.
Boehnke and his colleagues examined data from a 2017 report by the National Academies of Sciences, Engineering and Medicine on medical use of marijuana (cannabis). That report found conclusive or substantial evidence that marijuana eased chronic pain, nausea and vomiting due to chemotherapy, and muscle spasms of multiple sclerosis.
Though the number of registered U.S. medical marijuana patients rose from more than 641,000 in 2016 to nearly 814,000 in 2017, researchers said that’s likely far lower than the actual number of users.
Researchers said the finding is consistent with the prevalence of chronic pain, which affects an estimated 100 million Americans.
She told the Associated Press that on bad days, her muscles feel like they’re being squeezed in a vise. She said she stopped taking opioid painkillers because marijuana works better for her. She spends about $300 a month at her marijuana dispensary.
“Cannabis is the first thing I’ve found that actually makes the pain go away and not leave me so high that I can’t enjoy my day,” Smith told the AP.
As of 2018, medical marijuana use is legal in 33 states and the District of Columbia, while recreational use is legal in 10 states. The federal government still classifies pot as a drug, however, with no currently accepted medical use and a high potential for abuse.
“Since the majority of states in the U.S. have legalized medical cannabis, we should consider how best to adequately regulate cannabis and safely incorporate cannabis into medical practice,” Boehnke said in a University of Michigan news release.
The study was published in the February issue of the journal Health Affairs.
— Robert Preidt
Copyright © 2019 HealthDay. All rights reserved.
SOURCES: University of Michigan, news release, Feb. 4, 2019; Associated Press, Feb. 4, 2019